开拓药业(09939.HK)与Gensun订立独家许可协议
开拓药业-B(09939.HK)公布,与泽璟生物制药附属Gensun订立许可协议。据此,集团获独家许可,以利用化合物GS19 PLB-1C进行产品研发、制造及商业化,以及在使用化合物时制造、出售许可产品,并以其他方式利用许可权利,用於预防、治愈或改善位於大中华的任何人类疾病或医疗状况。Gensun有权收取400万美元的预付款,而集团须於达成相关里程碑事件时支付总计1,900万美元款项。
化合物是由拮抗剂抗体及胞外域组成的双标靶抗体。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.